Intellia Therapeutics, Inc.

NTLA Nasdaq CIK: 0001652130

Company Information

Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Large accelerated filer
State of Incorporation DE
Business Address 40 ERIE STREET, CAMBRIDGE, MA, 02139
Mailing Address 40 ERIE STREET, CAMBRIDGE, MA, 02139
Phone 857-285-6200
Fiscal Year End 1231
EIN 364785571

Financial Overview

FY2024

$523.51M
Cash & Equivalents

Recent SEC Filings

Form Type Date Filed Document
SCHEDULE 13G/A Passive ownership amendment February 12, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 11, 2026 View on SEC
SCHEDULE 13G Passive beneficial ownership (>5%) February 9, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment February 3, 2026 View on SEC
SCHEDULE 13G/A Passive ownership amendment January 30, 2026 View on SEC
8-K Current report of material events January 27, 2026 View on SEC
8-K Current report of material events January 9, 2026 View on SEC
4 Insider stock transaction report January 7, 2026 View on SEC
4 Insider stock transaction report January 7, 2026 View on SEC
4 Insider stock transaction report January 7, 2026 View on SEC

Insider Trading

SELL 8 insiders 11 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2835)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.